Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas B Julian

Showing results (1-10 of 91) with videos related to

Pageof 10
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2009
If sentinel node micrometastases are the question, are clinical trials the answer?Thomas B Julian
Journal of the National Cancer Institute|December 11, 2012
Does predicting positive nonsentinel nodes answer the question of axillary dissection and provide a benefit?Carol Slomski, Thomas B Julian
The Breast Journal|September 8, 2019
The ongoing evaluation and evolution of breast cancer surgical careMarielle Ferstenberg, Thomas B Julian
Clinical Breast Cancer|October 9, 2007
Ductal carcinoma in situ: biology, diagnosis, and new therapiesMarcia Valenzuela, Thomas B Julian
The Breast Journal|April 1, 2008
Neo-adjuvant hormonal therapyMarcia Valenzuela, Thomas B Julian
Journal of the National Cancer Institute|May 4, 2013
A multigene expression assay to predict local recurrence risk for ductal carcinoma in situShivani Duggal, Thomas B Julian
Current Oncology Reports|December 17, 2008
Completion of axillary dissection for a positive sentinel node: necessary or not?Kathleen M Erb, Thomas B Julian
Journal of the National Cancer Institute|September 27, 2013
Ductal carcinoma in situ: a rose by any other nameD Lawrence Wickerham, Thomas B Julian
Journal of the National Cancer Institute|October 16, 2003
Practice patterns of sentinel node biopsy at five comprehensive cancer centersDavid N Krag, Thomas B Julian
Expert Review of Anticancer Therapy|August 30, 2013
Ductal carcinoma in situ: an overviewShivani Duggal, Julieta Robin, Thomas B Julian
Pageof 10

Showing results (1-10 of 91) with videos related to

Sort By:
Pageof 10
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2009
If sentinel node micrometastases are the question, are clinical trials the answer?Thomas B Julian
Journal of the National Cancer Institute|December 11, 2012
Does predicting positive nonsentinel nodes answer the question of axillary dissection and provide a benefit?Carol Slomski, Thomas B Julian
The Breast Journal|September 8, 2019
The ongoing evaluation and evolution of breast cancer surgical careMarielle Ferstenberg, Thomas B Julian
Clinical Breast Cancer|October 9, 2007
Ductal carcinoma in situ: biology, diagnosis, and new therapiesMarcia Valenzuela, Thomas B Julian
The Breast Journal|April 1, 2008
Neo-adjuvant hormonal therapyMarcia Valenzuela, Thomas B Julian
Journal of the National Cancer Institute|May 4, 2013
A multigene expression assay to predict local recurrence risk for ductal carcinoma in situShivani Duggal, Thomas B Julian
Current Oncology Reports|December 17, 2008
Completion of axillary dissection for a positive sentinel node: necessary or not?Kathleen M Erb, Thomas B Julian
Journal of the National Cancer Institute|September 27, 2013
Ductal carcinoma in situ: a rose by any other nameD Lawrence Wickerham, Thomas B Julian
Journal of the National Cancer Institute|October 16, 2003
Practice patterns of sentinel node biopsy at five comprehensive cancer centersDavid N Krag, Thomas B Julian
Expert Review of Anticancer Therapy|August 30, 2013
Ductal carcinoma in situ: an overviewShivani Duggal, Julieta Robin, Thomas B Julian
Pageof 10